» Articles » PMID: 31638237

Comprehensive Analysis of the LncRNA‑associated Competing Endogenous RNA Network in Breast Cancer

Overview
Journal Oncol Rep
Specialty Oncology
Date 2019 Oct 23
PMID 31638237
Citations 27
Authors
Affiliations
Soon will be listed here.
Abstract

Long noncoding RNAs (lncRNAs) have been confirmed to be potential prognostic markers in a variety of cancers and to interact with microRNAs (miRNAs) as competing endogenous RNAs (ceRNAs) to regulate target gene expression. However, the role of lncRNA‑mediated ceRNAs in breast cancer (BC) remains unclear. In the present study, a ceRNA network was generated to explore their role in BC. The expression profiles of mRNAs, miRNAs and lncRNAs in 1,109 BC tissues and 113 normal breast tissues were obtained from The Cancer Genome Atlas database (TCGA). A total of 3,198 differentially expressed (DE) mRNAs, 150 differentially DEmiRNAs and 1,043 DElncRNAs were identified between BC and normal tissues. A lncRNA‑miRNA‑mRNA network associated with BC was successfully constructed based on the combined data obtained from RNA databases, and comprised 97 lncRNA nodes, 24 miRNA nodes and 74 mRNA nodes. The biological functions of the 74 DEmRNAs were further investigated by Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis. The results demonstrated that the DEmRNAs were significantly enriched in two GO biological process categories; the main biological process enriched term was 'positive regulation of GTPase activity'. By KEGG analysis, four key enriched pathways were obtained, including the 'MAPK signaling pathway', the 'Ras signaling pathway', 'prostate cancer', and the 'FoxO signaling pathway'. Kaplan‑Meier survival analysis revealed that six DElncRNAs (INC AC112721.1, LINC00536, MIR7‑3HG, ADAMTS9‑AS1, AL356479.1 and LINC00466), nine DEmRNAs (KPNA2, RACGAP1, SHCBP1, ZNF367, NTRK2, ORS1, PTGS2, RASGRP1 and SFRP1) and two DEmiRNAs (hsa‑miR‑301b and hsa‑miR‑204) had significant effects on overall survival in BC. The present results demonstrated the aberrant expression of INC AC112721.1, AL356479.1, LINC00466 and MIR7‑3HG in BC, indicating their potential prognostic role in patients with BC.

Citing Articles

Integration analysis of - and -regulatory long non-coding RNAs associated with immune-related pathways in non-small cell lung cancer.

Liu Y, Yang H, Lv G, Duan J, Zhao W, Shi Y Biochem Biophys Rep. 2024; 40:101832.

PMID: 39539669 PMC: 11558640. DOI: 10.1016/j.bbrep.2024.101832.


High NTRK2 protein expression levels may be associated with poorer prognosis of breast cancer patients.

Zhang R, Zhao J, Zhao L J Int Med Res. 2024; 52(9):3000605241281322.

PMID: 39340251 PMC: 11440626. DOI: 10.1177/03000605241281322.


Exploring the multifaceted role of RASGRP1 in disease: immune, neural, metabolic, and oncogenic perspectives.

Fan S, Kang B, Li S, Li W, Chen C, Chen J Cell Cycle. 2024; 23(6):722-746.

PMID: 38865342 PMC: 11229727. DOI: 10.1080/15384101.2024.2366009.


LncRNA LINC00466 Promotes the Progression of Breast Cancer miR-4731-5p/EPHA2 Pathway.

Han X, Shi F, Guo S, Li Y, Wang H, Song C Curr Pharm Biotechnol. 2024; 26(1):120-131.

PMID: 38726776 DOI: 10.2174/0113892010290582240419051056.


Long non-coding RNA MEG3 acts as a suppressor in breast cancer by regulating miR-330/CNN1.

Yi D, Wang Z, Yang H, Wang R, Shi X, Liu Z Aging (Albany NY). 2024; 16(2):1318-1335.

PMID: 38240701 PMC: 10866439. DOI: 10.18632/aging.205419.


References
1.
Tuba Sengel-Turk C, Hascicek C, Bakar F, Simsek E . Comparative Evaluation of Nimesulide-Loaded Nanoparticles for Anticancer Activity Against Breast Cancer Cells. AAPS PharmSciTech. 2016; 18(2):393-403. DOI: 10.1208/s12249-016-0514-2. View

2.
Zhu N, Hou J, Wu Y, Liu J, Li G, Zhao W . Integrated analysis of a competing endogenous RNA network reveals key lncRNAs as potential prognostic biomarkers for human bladder cancer. Medicine (Baltimore). 2018; 97(35):e11887. PMC: 6392549. DOI: 10.1097/MD.0000000000011887. View

3.
Kroenke C, Michael Y, Poole E, Kwan M, Nechuta S, Leas E . Postdiagnosis social networks and breast cancer mortality in the After Breast Cancer Pooling Project. Cancer. 2016; 123(7):1228-1237. PMC: 5360517. DOI: 10.1002/cncr.30440. View

4.
Luschin G, Habersack M . Oral information about side effects of endocrine therapy for early breast cancer patients at initial consultation and first follow-up visit: an online survey. Health Commun. 2013; 29(4):421-6. DOI: 10.1080/10410236.2012.743096. View

5.
Chiu Y, Hsiao T, Chen Y, Chuang E . Parameter optimization for constructing competing endogenous RNA regulatory network in glioblastoma multiforme and other cancers. BMC Genomics. 2015; 16 Suppl 4:S1. PMC: 4416191. DOI: 10.1186/1471-2164-16-S4-S1. View